Niraparib plus Abiraterone acetate plus Prednisone

Phase 3

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AZNPhase 3$256.5B

Niraparib plus Abiraterone acetate plus Prednisone Phase 3 Est. Readout (ProBio)

Niraparib plus Abiraterone acetate plus Prednisone• Metastatic Castration-resistant Prostate Cancer (mCRPC)750

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic Castration-resistant Prostate Cancer (mCRPC)

View Full Landscape

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical Trial

NCT03903835

Last updated: 10/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Saruparib (AZD5305)Phase 3

Ovarian Cancer

Ceftaroline fosamilPhase 3

Infections

AZD1152Phase 3

Acute Myeloid Leukemia

ChemotherapyPhase 3

Anticancer Treatment

exenatide twice dailyPhase 3

Type 2 Diabetes Mellitus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts